<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648165</url>
  </required_header>
  <id_info>
    <org_study_id>HSØ-2015056</org_study_id>
    <nct_id>NCT02648165</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure</brief_title>
  <official_title>Secondary Prevention of Depression Through Group-based Acceptance and Commitment Therapy Preceded by an Experimental Attentional Bias Modification Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wichita State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression (major depressive disorder; MDD) is a very common mental disorder. Research
      suggests that individuals with prior depressive episodes have a risk of the relapse or
      recurrence of MDD. Secondary prevention has been identified as a key goal in the long-term
      management of the disease. The current project aims to investigate whether group based
      Acceptance and Commitment Therapy (ACT) can reduce surrogate and clinical markers of relapse
      in a group highly vulnerable to depressive episodes. The group intervention will consist of
      eight sessions, and each group will consist of maximum 12 persons. The project also studies
      whether Attention Bias Modification (ABM) preceding the ACT intervention will enhance the
      effect. ABM will be administered over a fourteen days period prior to the ACT-intervention.
      Effect will be measured over a period of 12 months. The primary outcome is changes in
      depressive symptoms. ACT-specific secondary outcome measures are also included. Subjects with
      a history of major depression (n=200), currently in remission, will be recruited from
      Sørlandet Hospital (100 participants). Matched participants (100 participants) will be
      recruited at the University of Oslo. In the first phase, participants from Sørlandet hospital
      will be randomized to ABM treatment or control condition. In the second phase all
      participants from Sørlandet hospital will receive group based ACT treatment. Group based ACT
      and ABM represent interventions that are time and cost effective, and that could be made
      available to large number of individuals struggling with MDD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in residual symptoms of depression - self report</measure>
    <time_frame>Will be measured at Baseline, immediately after ABM-intervention, then after 1 month, 2 months, 6 months, and 12 months</time_frame>
    <description>Change in residual symptoms of depression as measured by Beck Depression Inventory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in residual symptoms of depression - clinician rating</measure>
    <time_frame>Will be measured at Baseline, immediately after ABM-intervention, then after 1 month, 2 months, 6 months, and 12 months</time_frame>
    <description>Change in residual symptoms of depression as rated by Hamilton Rating Scale for Depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of major depressive episodes</measure>
    <time_frame>Will be measured 12 months after baseline</time_frame>
    <description>Measured by MINI structured interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cortisol response</measure>
    <time_frame>Will be measured at Baseline, immediately after ABM-intervention, then after 1 month, 2 months, 6 months, and 12 months</time_frame>
    <description>Cortisol measured in salvia. Samples taken in the morning on three days in succession.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in symptoms of anxiety - self report</measure>
    <time_frame>Will be measured at Baseline, immediately after ABM-intervention, then after 1 month, 2 months, 6 months, and 12 months</time_frame>
    <description>Change in symptoms of anxiety as measured by Beck Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life - self report</measure>
    <time_frame>Will be measured at Baseline, then after 2 months, 6 months, and 12 months</time_frame>
    <description>WHOQOL-BREF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Acceptance - self report</measure>
    <time_frame>Will be measured at Baseline, then after 1 month, 2 months, 6 months, 12 months</time_frame>
    <description>The 7-item Acceptance and Action Questionnaire - II (AAQ-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Values - self report</measure>
    <time_frame>Will be measured at Baseline, then after 1 month, 2 months, 6 months, 12 months</time_frame>
    <description>Bulls Eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Values and committed action - self report</measure>
    <time_frame>Will be measured at Baseline, then after 1 month, 2 months, 6 months, 12 months</time_frame>
    <description>Engaged living scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Emotional, Psychological and Social Well-Being - self report</measure>
    <time_frame>Will be measured at Baseline, then after 1 month, 2 months, 6 months, 12 months</time_frame>
    <description>Mental Health continuum - short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Present-moment awareness and acceptance - self report</measure>
    <time_frame>Will be measured at Baseline, then after 1 month, 2 months, 6 months, 12 months (only in ACT-arms)</time_frame>
    <description>Philadelphia mindfulness scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cognitive fusion - self report</measure>
    <time_frame>1 month, 2 months, 6 months, 12 months (only in ACT-arms)</time_frame>
    <description>Cognitive fusion questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>ABM +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attention Bias Modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABM -</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Attention Bias Modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABM + and ACT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attention Bias Modification followed by Group Acceptance and Commitment Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABM - and ACT</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attention Bias Modification</intervention_name>
    <description>Computer based Attention Bias Modification</description>
    <arm_group_label>ABM +</arm_group_label>
    <arm_group_label>ABM + and ACT</arm_group_label>
    <other_name>ABM+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sham Attention Bias Modification</intervention_name>
    <description>Computer based Sham Attention Bias Modification</description>
    <arm_group_label>ABM -</arm_group_label>
    <arm_group_label>ABM - and ACT</arm_group_label>
    <other_name>ABM-</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Acceptance and Commitment Therapy</intervention_name>
    <description>Acceptance and Commitment Therapy delivered in a group therapy setting</description>
    <arm_group_label>ABM + and ACT</arm_group_label>
    <arm_group_label>ABM - and ACT</arm_group_label>
    <other_name>ACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a history of major depression, currently in remission

        Exclusion Criteria:

          -  Current or past neurological illness, bipolar disorder, psychosis or drug addiction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Ø Haaland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sørlandet Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vegard Ø. Haaland, PhD</last_name>
    <phone>+47 40454145</phone>
    <email>vegard.oksendal.haaland@sshf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Østergaard, CandPsychol</last_name>
    <phone>+47 450 65 556</phone>
    <email>tom.Ostergaard@sshf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sørlandet Hospital, Department of Psychiatry</name>
      <address>
        <city>Arendal</city>
        <state>Aust-Agder</state>
        <zip>4801</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vegard Ø Haaland, PhD</last_name>
      <phone>+47 40454145</phone>
      <email>vegard.oksendal.haaland@sshf.no</email>
    </contact>
    <contact_backup>
      <last_name>Tom Østergaard, Cand.psychol</last_name>
      <phone>+47 450 65 556</phone>
      <email>tom.Ostergaard@sshf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Oslo, Department of Psychology</name>
      <address>
        <city>Oslo</city>
        <zip>0317</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nils I Landrø, Dr. Phil</last_name>
      <phone>+47 22 84 51 46</phone>
      <email>n.i.landro@psykologi.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Rune Jonassen, PhD</last_name>
      <phone>+47 905 23 407</phone>
      <email>rune.jonassen@psykologi.uio.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sorlandet Hospital HF</investigator_affiliation>
    <investigator_full_name>Vegard Haaland</investigator_full_name>
    <investigator_title>Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

